|
Canada-0-Insurance företaget Kataloger
|
Företag Nyheter:
- Bayer - myGenAssist
Please contact your administrator for assistance ChatGPT but better
- About Us — GenAssist
Orthopedic trauma surgeons, reconstructive plastic surgeons, urogynecologists, and Physical Medicine Rehabilitation (PM R) physicians can use GenAssist’s patented flagship technology, MyoMatrix, to heal muscle wounds from high-impact trauma, disease, and other injuries
- Home | Genassist Therapeutics
GenAssist Ltd (GenAssist) is a pioneering gene editing drug company founded in 2020 in Suzhou Industrial Park, Suzhou, China Suzhou GenAssist Therapeutic Co , Ltd is the operation entity of GenAssist
- GenAssist Ltd Announces FDA Clearance of Investigational New Drug . . .
GenAssist is planning to conduct clinical study globally for GEN6050X "FDA clearance of our first IND is a significant milestone for our company
- GenAssist Ltd Announced the First DMD Patient Dosed with its Base . . .
GenAssist owns the global rights of Targeted AID-mediated Mutagenesis cytosine base editor technology The company is dedicated to developing base editing drugs against life-threatening diseases
- Meet myGenAssist: AI Support Tailored for #TeamBayer
Ever wanted a personal assistant at work to help you achieve even better results?Meet myGenAssist - Bayer’s internal secure GenAI platform, designed to work
- GenAssist Therapeutics 2026 Company Profile: Valuation, Funding . . .
Information on valuation, funding, cap tables, investors, and executives for GenAssist Therapeutics Use the PitchBook Platform to explore the full profile
- GenAssist Announces FDA Approval of New Drug Application for GEN6050X . . .
We are excited about the potential of this program to bring new treatment for patients and demonstrate gene editing as a new therapeutic approach for DMD In addition, GenAssist is advancing other DMD exon-skipping programs, which cover more than 30% DMD population ”
|
|